Stacey Bain
Directeur/Membre du Conseil chez Catalyst Canada, Inc.
Profil
Stacey Bain is currently a Director at Catalyst Canada, Inc. Prior to this, she held positions as Vice President-Clinical Product Development at BioNumerik Pharmaceuticals, Inc. and Vice President-Clinical Operations at Acer Therapeutics, Inc. She received a doctorate degree from Texas A&M University in 1998 and an undergraduate degree from the same institution in 1992.
Postes actifs de Stacey Bain
| Sociétés | Poste | Début |
|---|---|---|
Catalyst Canada, Inc.
 Catalyst Canada, Inc. Advertising/Marketing ServicesCommercial Services Part of Catalyst, Inc., Catalyst Canada, Inc. is a Canadian company that provides marketing and advertising services. The company is based in Toronto, Canada and was founded in 2000. | Directeur/Membre du Conseil | - |
Anciens postes connus de Stacey Bain
| Sociétés | Poste | Fin |
|---|---|---|
| ACER THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | - |
BioNumerik Pharmaceuticals, Inc.
 BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Corporate Officer/Principal | - |
Formation de Stacey Bain
| Texas A&M University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
BioNumerik Pharmaceuticals, Inc.
BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Health Technology |
Acer Therapeutics, Inc.
 Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
Catalyst Canada, Inc.
Catalyst Canada, Inc. Advertising/Marketing ServicesCommercial Services Part of Catalyst, Inc., Catalyst Canada, Inc. is a Canadian company that provides marketing and advertising services. The company is based in Toronto, Canada and was founded in 2000. | Commercial Services |
